{"id":745047,"date":"2014-01-08T08:30:00","date_gmt":"2014-01-08T08:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/"},"modified":"2023-03-22T00:05:00","modified_gmt":"2023-03-22T04:05:00","slug":"merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/","title":{"rendered":"Merck Receives FDA Approval for ISENTRESS\u00ae (raltegravir) for Pediatric Oral Suspension"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that the U.S. Food and Drug Administration (FDA)<br \/>\n      recently approved ISENTRESS<sup>\u00ae<\/sup> for oral suspension, a new<br \/>\n      pediatric formulation of Merck\u2019s integrase inhibitor. With this<br \/>\n      approval, ISENTRESS is now indicated in combination with other<br \/>\n      antiretroviral (ARV) agents for the treatment of HIV-1 infection in<br \/>\n      patients four weeks of age and older. The use of other active agents<br \/>\n      with ISENTRESS is associated with a greater likelihood of treatment<br \/>\n      response. The oral suspension may be used in patients as young as four<br \/>\n      weeks of age, weighing at least 3 kg to less than 20 kg. The safety and<br \/>\n      efficacy of ISENTRESS have not been established in infants less than<br \/>\n      four weeks of age. Formulations of ISENTRESS for specific populations<br \/>\n      now include oral suspension, chewable tablets and film-coated tablets.\n    <\/p>\n<p>\n      \u201cWe are very pleased that ISENTRESS can now be a part of a treatment<br \/>\n      regimen for HIV-1 infected infants and children as young as four weeks<br \/>\n      of age,\u201d said Hedy Teppler, executive director, Clinical Research, Merck<br \/>\n      Research Laboratories.\n    <\/p>\n<p>\n      Merck anticipates that the oral suspension formulation will be available<br \/>\n      in the United States during the third quarter of 2014.\n    <\/p>\n<p>\n      <b>Important Selected Safety Information<\/b>\n    <\/p>\n<p>\n      ISENTRESS does not cure HIV-1 infection or AIDS.\n    <\/p>\n<p>\n      Severe, potentially life-threatening and fatal skin reactions have been<br \/>\n      reported.<sup> <\/sup>This includes cases of Stevens-Johnson syndrome,<br \/>\n      hypersensitivity reaction and toxic epidermal necrolysis.<sup> <\/sup>Immediately<br \/>\n      discontinue treatment with ISENTRESS (raltegravir) and other suspect<br \/>\n      agents if severe hypersensitivity, severe rash, or rash with systemic<br \/>\n      symptoms or liver aminotransferase elevations develop and monitor<br \/>\n      clinical status, including liver aminotransferases closely.\n    <\/p>\n<p>\n      Immune reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment.\n    <\/p>\n<p>\n      ISENTRESS chewable tablets contain phenylalanine, a component of<br \/>\n      aspartame, which may be harmful to patients with phenylketonuria.\n    <\/p>\n<p>\n      Co-administration of ISENTRESS with drugs that are strong inducers of<br \/>\n      uridine diphosphate glucuronosyltransferase (UGT1A1) may result in<br \/>\n      reduced plasma concentrations of raltegravir. Co-administration of<br \/>\n      ISENTRESS and other drugs may alter the plasma concentration of<br \/>\n      raltegravir. The potential for drug-drug interactions (DDIs) must be<br \/>\n      considered prior to and during therapy. Co-administration or staggered<br \/>\n      administration (by 2 hours) of aluminum and\/or magnesium<br \/>\n      hydroxide-containing antacids and ISENTRESS is not recommended.<br \/>\n      Rifampin, a strong inducer of UGT1A1, reduces plasma concentrations of<br \/>\n      ISENTRESS. Therefore, the dose of ISENTRESS for adults should be<br \/>\n      increased to 800 mg twice daily during coadministration with rifampin.<br \/>\n      There are no data to guide co-administration of ISENTRESS with rifampin<br \/>\n      in patients below 18 years of age.\n    <\/p>\n<p>\n      The most commonly reported (\u22652%) drug-related clinical adverse reactions<br \/>\n      of moderate to severe intensity in treatment-na\u00efve adult patients<br \/>\n      receiving ISENTRESS compared with efavirenz were insomnia (4% vs 4%),<br \/>\n      headache (4% vs 5%), nausea (3% vs 4%), fatigue (2% vs 3%) and dizziness<br \/>\n      (2% vs 6%), respectively. In treatment-experienced adult patients<br \/>\n      receiving ISENTRESS, the most commonly reported (\u22652% in either treatment<br \/>\n      group) drug-related clinical adverse reactions of moderate to severe<br \/>\n      intensity and at a higher incidence compared with placebo was headache<br \/>\n      (2% vs 1%). Intensities were defined as follows: Moderate (discomfort<br \/>\n      enough to cause interference with usual activity); or Severe<br \/>\n      (incapacitating with inability to work or do usual activity).<sup> <\/sup>In<br \/>\n      treatment-experienced children and adolescents four weeks through 18<br \/>\n      years of age receiving ISENTRESS, the frequency, type and severity of<br \/>\n      drug-related adverse reactions were comparable to those observed in<br \/>\n      adults.\n    <\/p>\n<p>\n      Grade 2 to 4 creatine kinase laboratory abnormalities were observed in<br \/>\n      patients treated with ISENTRESS. Myopathy and rhabdomyolysis have been<br \/>\n      reported. Use with caution in patients at increased risk of myopathy or<br \/>\n      rhabdomyolysis, such as patients receiving concomitant medications known<br \/>\n      to cause these conditions and patients with a history of rhabdomyolysis,<br \/>\n      myopathy or increased serum creatine kinase.\n    <\/p>\n<p>\n      Rash occurred more commonly in treatment-experienced subjects receiving<br \/>\n      regimens containing ISENTRESS (raltegravir) plus darunavir\/ritonavir,<br \/>\n      compared to subjects receiving ISENTRESS without darunavir\/ritonavir or<br \/>\n      darunavir\/ritonavir without ISENTRESS. However, rash that was considered<br \/>\n      drug-related occurred at similar rates for all three groups. These<br \/>\n      rashes were mild to moderate in severity and did not limit therapy;<br \/>\n      there were no discontinuations due to rash.\n    <\/p>\n<p>\n      ISENTRESS should be used during pregnancy only if the potential benefit<br \/>\n      justifies the potential risk to the fetus.<sup> <\/sup>To monitor<br \/>\n      maternal-fetal outcomes of pregnant patients exposed to ISENTRESS, an<br \/>\n      Antiretroviral Pregnancy Registry has been established. Physicians are<br \/>\n      encouraged to register patients by calling 1-800-258-4263.\n    <\/p>\n<p>\n      <b>About ISENTRESS<\/b>\n    <\/p>\n<p>\n      ISENTRESS is Merck&#8217;s integrase inhibitor for the treatment of HIV-1<br \/>\n      infection in adult and pediatric patients ages four weeks and older and<br \/>\n      weighing at least 3 kg as part of combination HIV therapy. ISENTRESS<br \/>\n      works by inhibiting the insertion of HIV-1 DNA into human DNA by the<br \/>\n      integrase enzyme and has demonstrated rapid antiviral activity.<sup> <\/sup>Inhibiting<br \/>\n      integrase from performing this essential function limits the ability of<br \/>\n      the virus to replicate and infect new cells.<b> <\/b>ISENTRESS is now<br \/>\n      approved as part of combination therapy in more than 76 countries for<br \/>\n      use in treatment-na\u00efve adult patients with HIV-1 and in more than 114<br \/>\n      countries for use in treatment-experienced adult patients with HIV-1.<br \/>\n      ISENTRESS, in combination therapy, for use in children and adolescents<br \/>\n      with HIV-1 ages two years and older has also been approved for use in 35<br \/>\n      countries. Merck is continuing to move forward with filings of ISENTRESS<br \/>\n      for oral suspension in additional countries around the world.\n    <\/p>\n<p>\n      To assist patients taking ISENTRESS, Merck offers the SUPPORT\u2122 program,<br \/>\n      which provides personal support and patient advocacy regarding<br \/>\n      individual reimbursement issues. For more information about the SUPPORT\u2122<br \/>\n      program, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.merckhelps.com&#038;esheet=50778712&#038;newsitemid=20140108005210&#038;lan=en-US&#038;anchor=www.merckhelps.com&#038;index=1&#038;md5=c9b47691fe19cb4fccedc8eb73d3dc45\" rel=\"nofollow\">www.merckhelps.com<\/a><br \/>\n      or call 1-800-850-3430.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50778712&#038;newsitemid=20140108005210&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=2&#038;md5=57669dbe832c84c9e32b823b45d909a1\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50778712&#038;newsitemid=20140108005210&#038;lan=en-US&#038;anchor=Twitter&#038;index=3&#038;md5=c9bf983173be9d86d50155e0223898bd\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50778712&#038;newsitemid=20140108005210&#038;lan=en-US&#038;anchor=Facebook&#038;index=4&#038;md5=10120df75758926ab23c6b63aaddda04\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50778712&#038;newsitemid=20140108005210&#038;lan=en-US&#038;anchor=YouTube&#038;index=5&#038;md5=c3e974887e74d2fce8c9d186ff8f3a4e\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50778712&#038;newsitemid=20140108005210&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=6&#038;md5=4adfba7ce44e6f97c010d38f9497f912\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ISENTRESS (raltegravir) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_pi.pdf&#038;esheet=50778712&#038;newsitemid=20140108005210&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_pi.pdf&#038;index=7&#038;md5=0d1c2179eaa6fbc18731e1c1dbebb85b\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/i\/isentress\/isentress_pi.pdf<\/b><\/a><b><br \/>\n      and Patient Information for ISENTRESS at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ppi.pdf&#038;esheet=50778712&#038;newsitemid=20140108005210&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fi%2Fisentress%2Fisentress_ppi.pdf&#038;index=8&#038;md5=12d9f2db440296348a6310ed2cf674d7\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/i\/isentress\/isentress_ppi.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p>\n      <b>ISENTRESS<\/b><sup><b>\u00ae<\/b><\/sup><b> is a registered trademark of<br \/>\n      Merck &#038; Co., Inc., Whitehouse Station, N.J., USA<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20140108005210r1&#038;sid=hq1sf1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Sarra        Herzog, 908-423-6154<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) recently approved ISENTRESS \u00ae for oral suspension, a new pediatric formulation of Merck\u2019s integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients four weeks of age and older. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response. The oral suspension may be used in patients as young as four weeks of age, weighing at least 3 kg to less than 20 kg. The safety and efficacy of ISENTRESS have not been established in infants less than four weeks of age. Formulations of ISENTRESS for specific populations now include oral suspension, chewable tablets and film-coated tablets. \u201cWe are very pleased that ISENTRESS can now be a part of a treatment regimen for HIV-1 infected infants and children as<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289],"class_list":["post-745047","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Receives FDA Approval for ISENTRESS\u00ae (raltegravir) for Pediatric Oral Suspension - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Receives FDA Approval for ISENTRESS\u00ae (raltegravir) for Pediatric Oral Suspension - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) recently approved ISENTRESS \u00ae for oral suspension, a new pediatric formulation of Merck\u2019s integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients four weeks of age and older. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response. The oral suspension may be used in patients as young as four weeks of age, weighing at least 3 kg to less than 20 kg. The safety and efficacy of ISENTRESS have not been established in infants less than four weeks of age. Formulations of ISENTRESS for specific populations now include oral suspension, chewable tablets and film-coated tablets. \u201cWe are very pleased that ISENTRESS can now be a part of a treatment regimen for HIV-1 infected infants and children as\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:05:00+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140108005210r1&sid=hq1sf1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\\\/\",\"name\":\"Merck Receives FDA Approval for ISENTRESS\u00ae (raltegravir) for Pediatric Oral Suspension - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140108005210r1&sid=hq1sf1&distro=nx\",\"datePublished\":\"2014-01-08T08:30:00+00:00\",\"dateModified\":\"2023-03-22T04:05:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140108005210r1&sid=hq1sf1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140108005210r1&sid=hq1sf1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Receives FDA Approval for ISENTRESS\u00ae (raltegravir) for Pediatric Oral Suspension\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Receives FDA Approval for ISENTRESS\u00ae (raltegravir) for Pediatric Oral Suspension - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/","og_locale":"en_US","og_type":"article","og_title":"Merck Receives FDA Approval for ISENTRESS\u00ae (raltegravir) for Pediatric Oral Suspension - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) recently approved ISENTRESS \u00ae for oral suspension, a new pediatric formulation of Merck\u2019s integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients four weeks of age and older. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response. The oral suspension may be used in patients as young as four weeks of age, weighing at least 3 kg to less than 20 kg. The safety and efficacy of ISENTRESS have not been established in infants less than four weeks of age. Formulations of ISENTRESS for specific populations now include oral suspension, chewable tablets and film-coated tablets. \u201cWe are very pleased that ISENTRESS can now be a part of a treatment regimen for HIV-1 infected infants and children as","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:05:00+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140108005210r1&sid=hq1sf1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/","name":"Merck Receives FDA Approval for ISENTRESS\u00ae (raltegravir) for Pediatric Oral Suspension - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140108005210r1&sid=hq1sf1&distro=nx","datePublished":"2014-01-08T08:30:00+00:00","dateModified":"2023-03-22T04:05:00+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140108005210r1&sid=hq1sf1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140108005210r1&sid=hq1sf1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-fda-approval-for-isentress-raltegravir-for-pediatric-oral-suspension\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Receives FDA Approval for ISENTRESS\u00ae (raltegravir) for Pediatric Oral Suspension"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"885d486b-98d5-46de-b04e-e3a91ab8cc6b","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745047\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745047"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}